Novel Drug Delivery Strategies in Neuro-Oncology

Neurotherapeutics

Volumn 6, Issue 3, 2009, Pages 539-546

  Bidros, Dani S ^a   Vogelbaum, Michael A ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

blood brain barrier disruption; brain neoplasm; Convection enhanced delivery; drug delivery system

Indexed keywords

ANTINEOPLASTIC AGENT; AP 12009; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBOPLATIN; CARMUSTINE; CINTREDEKIN BESUDOTOX; DEXTRAN; DIPHTHERIA TOXIN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; IMMUNOTOXIN; INTERLEUKIN 4; LOBRADIMIL; MANNITOL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NIMUSTINE; PACLITAXEL; PARVOVIRUS VECTOR; POLYMER; PRX 321; PSEUDOMONAS EXOTOXIN; TEMOZOLOMIDE; THYMIDINE KINASE; TOPOTECAN; TP 38; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONVECTION ENHANCED DELIVERY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BRAIN LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; INTERSTITIAL DRUG ADMINISTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; PANCREAS CARCINOMA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SURVIVAL TIME; ULTRASOUND; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CATHETERIZATION; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EXOTOXINS; GENETIC VECTORS; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOTOXINS; INTERLEUKINS; TRANSFERRIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; ULTRASONIC THERAPY;

EID: 67649133075     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.04.004     Document Type: Article

References (56)

1. Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 2000-2004 (2005), Central Brain Tumor Registry of the United States, Chicago
2. Central Nervous System Cancers Practice Guidelines in Oncology (2005), National Comprehensive Cancer Network, Jenkintown, PA Vol 2
3. Nieder C., Grosu A.L., and Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Rev 26 (2000) 397-409
4. Nicholas M.K., Prados M.D., Larson D.A., and Gutin P.H. Malignant astrocytomas. In: Black P.MCL., and Loeffler J.S. (Eds). Cancer of the nervous system (1997), Blackwell Science, Cambridge 464-491
5. Greenwood J. Experimental manipulation of the blood-brain and blood-retinal barriers. In: Bradbury M.W.B. (Ed). physiology and pharmacology of the blood-brain barrier (1992), Springer-Verlag, Germany 459-486
6. Neuwelt E.A. Mechanisms of disease: The blood-brain barrier. Neurosurgery 54 (2004) 131-142
7. Rapoport S.L., and Robinson P.J. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann NY Acad Sci 481 (1987) 250-267
8. Williams P.C., Henner W.D., Roman-Goldstein S., et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37 (1995) 17-28
9. Neuwelt E.A., Frenkel E.P., Rapoport S.I., et al. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 7 (1980) 36-43
10. Dahlborg S.A., Henner W.D., Crossen J.R., et al. Non-AIDS primary CNS lymphoma: The first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2 (1996) 168-174
11. Kraemer D.F., Fortin D., Doolittle N.D., et al. Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurgery 48 (2001) 1033-1041
12. McAllister L.D., Doolittle N.D., Guastadisegni P.E., et al. Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 46 (2000) 51-61
13. Neuwelt E.A., Goldman D.L., Dahlborg S.A., et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9 (1991) 1580-1590
14. Neuwelt E.A., Barnett P.A., Glasberg M., et al. Pharmacology and neurotoxicity of Cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 43 (1983) 5278-5285
15. Cloughesy T.F., and Black K.L. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26 (1995) 125-132
16. Bartus R.T., Elliott P.J., Dean R.L., et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 142 (1996) 14-28
17. Ford J., Osborn C., Barton T., and Bleehan N.M. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34 (1998) 1807-1811
18. Hynynen K., Clement G.T., McDonald N., et al. 500-element ultrasound phased array system for noninvasive focal surgery of the brain: A preliminary rabbit study with ex vivo human skulls. Magn Reson Med 52 (2004) 100-107
19. Hynynen K., McDannold N., Vykhodtseva N., et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220 (2001) 640-646
20. Treat L.H., McDannold N., and Hynynen K. Transcranial MRI-guided focused ultrasound-induced blood-brain barrier opening in rats (2:998-1000). IEEE Ultrasonics Symposium (2004) Montreal, Canada, August 24-27
21. Clement G.T., and Hynynen K. A noninvasive method for focusing ultrasound through the human skull. Phys Med Biol 47 (2000) 1219-1236
22. Brem H., Mahaley Jr. M.S., Vick N.A., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74 (1991) 441-446
23. Executive Committee of the Gliadel Study Group, Westphal M., Ram Z., Riddle V., Hilt D., and Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148 3 (2006) 269-275
24. Walter K.A., Cahan M.A., Gur A., et al. Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54 (1994) 2207-2212
25. Watts D.J., Lesniak D.J., Burke D.J., et al. Controlled release of Adriamycin in the treatment of malignant glioma (poster). American Association of Neurological Surgeons Annual Meeting, Denver, CO (1997)
26. Menei P., Venier M.C., Gamelin E., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 86 (1999) 325-330
27. Tajika Y., Muragaki Y., Hiyama H., et al. Local chemotherapy with slowly-releasing anticancer drug polymers for malignant brain tumors. J Control Fel 32 (1994) 1-8
28. DeMeco F., Li K.W., Tyler B.M., et al. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 97 (2002) 1173-1178
29. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 15 91(6) (1994) 2076-2080
30. Cunningham J., Pivirotto P., Bringas I., et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 16 7 (2008) 1267-1275
31. Lonser R.R., Walbridge S., Garmestani K., et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97 4 (2002) 905-913
32. Chen M.Y., Lonser R.R., Morrison P.F., et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90 2 (1999) 315-320
33. Vogelbaum M.A. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 73 1 (2005) 57-69
34. Raghavan R., Brady M.L., Rodriquez-Ponce M.I., Hartlep A., Pedain C., and Sampson J.H. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20 4 (2006) E12
35. Oh S., Odland R., Wilson S., et al. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 107 (2007) 568-577
36. Hadaczek P., Kohutnicka M., Krauze M.T., et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17 3 (2006) 291-302
37. Sanftner L.M., Sommer J.M., Suzuki B.M., et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 194 2 (2005) 476-483
38. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100 3 (2004) 472-479
39. Kaiser M.G., Parsa A.T., Fine R.L., et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47 6 (2000) 1391-1398
40. Saito R., Krauze M.T., Noble C.O., et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol 8 3 (2006) 205-214
41. Laske D.W., Youle R.J., and Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3 (1997) 1362-1368
42. Weaver M., and Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65 1 (2002) 3-13
43. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir 88 (2003) 105-111
44. Debinski W., Obiri N., Pastan I., et al. A novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270 (1995) 16775-16780
45. Debinski W., Obiri N., Powers S., et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1 (1995) 1253-1258
46. Kunwar S., Chang S.M., Prados M.D., et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20 4 (2006) E15
47. Vogelbaum M.A. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol 83 (2007) 97-109
48. Kunwar M.S., Westphal T.A., Medhorn D.J., et al. Results from PRECISE: a randomized phase 3 study in patients with first recurrent glioblastoma multiforme (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with gliadel wafers (GW). Abstract from the Twelfth Annual Meeting of the Society for Neuro-Oncology (October, 2007)
49. Vogelbaum M.A., Sampson J.H., Kunwar S., et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61 (2007) 1031-1038
50. Kawakami M., Kawakami K., and Puri R.K. Interleukin-4-pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 5 1 (2003) 15-25
51. Weber F.W., Floeth F., Asher A., et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88 (2003) 93-103
52. Rand R.W., Kreitman R.J., Patronas N., et al. Intratumoral administration of recombinant circularly permuted interleukin-4-pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6 6 (2000) 2157-2165
53. Weber F., Asher A., Bucholz R., et al. Safety, toleratbility, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64 1-2 (2003) 125-137
54. Wong A.J., Bigner S.H., Bigner D.D., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci 84 19 (1987) 6899-6903
55. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 1 (2003) 27-35
56. Schlingensiepen K.H., Fischer-Blass B., Schmaus S., et al. Antisense therapeutics for tumor treatment: the TGF-beta 2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 177 (2008) 137-150